Next Article in Journal
Notch3 Transactivates Glycogen Synthase Kinase-3-Beta and Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer Cells
Next Article in Special Issue
Enhanced Activity of NLRP3 Inflammasome in the Lung of Patients with Anti-Synthetase Syndrome
Previous Article in Journal
Exosome Release by Glucose Deprivation Is Important for the Viability of TSC-Null Cells
Previous Article in Special Issue
Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942
 
 
Review
Peer-Review Record

Hashimoto Encephalopathy—Still More Questions than Answers

Cells 2022, 11(18), 2873; https://doi.org/10.3390/cells11182873
by Marta Waliszewska-Prosół * and Maria Ejma
Reviewer 1:
Reviewer 2: Anonymous
Cells 2022, 11(18), 2873; https://doi.org/10.3390/cells11182873
Submission received: 12 August 2022 / Revised: 5 September 2022 / Accepted: 12 September 2022 / Published: 14 September 2022
(This article belongs to the Special Issue Autoimmune Diseases: Molecular Mechanisms and Therapies)

Round 1

Reviewer 1 Report

Overall, this is an accurate, interesting and in-depth review of the recent literature about the thyroid–brain axis and the etiology, pathogenesis, and controversy surrounding Hashimoto encephalopathy, the most serious neurological complication of Hashimoto’s thyroiditis. Although the citations are numerous, relevant and updated, I would like the authors to deepen the pathogenesis of both Hashimoto's thyroiditis and Hashimoto encephalopathy by adding something about the role of T and B lymphocytes and explaining better what are the various pathogenetic steps that lead to these pathological conditions.

Author Response

Dear Editor,

Dear Reviewers,

 

Thank you for your efforts in processing our paper. We greatly appreciate reviewers’ thoughtful comments, which we believe have helped us to improve the paper substantially. Below we provide a point-by-point response to these comments. All changes in the manuscript have been marked with a track-changes mode.

On behalf of all authors,

Marta Waliszewska-ProsóÅ‚

Reviewer #1:

Point: Although the citations are numerous, relevant and updated, I would like the authors to deepen the pathogenesis of both Hashimoto's thyroiditis and Hashimoto encephalopathy by adding something about the role of T and B lymphocytes and explaining better what are the various pathogenetic steps that lead to these pathological conditions.

Response: This has been added to the text and in the Figure 1 as suggested.

Reviewer 2 Report

Overall, the aim of this review is unclear.

Methods

The author searched only for Hashimoto's encephalopathy and SERAT, while EAATD and NAIM are also the same disease concept. Many records may be underestimated.

Table1,

The classification of Hashimoto's encephalopathy into two types is interesting, but there is no evidence for the classification criteria. If the classification is what the authors wish to propose, they need to provide citations for the evidence.

Chapter 3.3.3. is titled Clinical Manifestations, but it also discusses laboratory and imaging findings.

Lin423, if imaging findings are to be positioned as important, the review should be written with that logic in mind, and other articles on imaging studies should be compared and evaluated.

 We recommend that you write your review around the areas you want to focus on, rather than summarizing what has often been said in previous reviews.

Author Response

Dear Editor,

 Dear Reviewers,

Thank you for your efforts in processing our paper. We greatly appreciate reviewers’ thoughtful comments, which we believe have helped us to improve the paper substantially. Below we provide a point-by-point response to these comments. All changes in the manuscript have been marked with a track-changes mode.

On behalf of all authors,

Marta Waliszewska-ProsóÅ‚

Reviewer #2:

Point: The author searched only for Hashimoto's encephalopathy and SERAT, while EAATD and NAIM are also the same disease concept. Many records may be underestimated.

Response: The terms EAATD and NAIM were also searched, our oversight in the methodology has already been corrected.

 

Point: Table1, The classification of Hashimoto's encephalopathy into two types is interesting, but there is no evidence for the classification criteria. If the classification is what the authors wish to propose, they need to provide citations for the evidence.

Response: The caption in the table description has been corrected that this is a conventional clinical division based on the literature as modified by the authors themselves.

Point: Chapter 3.3.3. is titled Clinical Manifestations, but it also discusses laboratory and imaging findings.

Response: Thank you for this comment. Actually, subsection 3.3.3. was imprecise. We have moved unnecessary information to other chapters.

Point: Lin423, if imaging findings are to be positioned as important, the review should be written with that logic in mind, and other articles on imaging studies should be compared and evaluated.

Response: We have changed the form in which this information is presented in the text.

 

Round 2

Reviewer 1 Report

The authors made the changes I suggested in a timely and thorough manner. The manuscript now is complete and exhaustive. 

Reviewer 2 Report

The author has provided appropriate responses and edited the paper with regard to the points raised.

There are no additional remarks.

Back to TopTop